By combining the varicella zoster virus (VZV) specific antigen (gE) with the AS01B adjuvant, Shingrix is designed to induce antigen-specific cellular and humoral immune responses in individuals with pre-existing immunity against VZV.
Say NO to SPAM Posts.
